BioSpace’s Post

Following strong Phase II data, Amgen is going all-in on its next-generation obesity treatment MariTide, with plans to run a Phase III trial and a separate mid-stage study for diabetes. Meanwhile, as Amgen accelerates the development of one obesity candidate, it has also terminated its work on an early-stage obesity pill: AMG 786. The pharma revealed in an investor call that it will no longer invest resources into the candidate after it failed to meet the company's expectations. In the first quarter of 2024, Amgen reported $7.4 billion in total revenues, up 22% from the same period the prior year. However, the pharma’s diluted earnings-per-share slid slightly to $3.96 in Q1, down from $3.98 during the same period in 2023. #biotech #biopharma #Obesity #WeightLoss #Survodutide #Earnings #Q1

Roche reaps the rewards of its $2.7 billion acquisition of Carmot Therapeutics in December 2023 as its investigational GLP-1/GIP receptor agonist induced strong weight loss in a Phase Ib study. The candidate, dubbed CT-388, lowered body weight by 18.8% versus placebo at 24 weeks. A subgroup analysis also showed that all pre-diabetic participants at the start of the study achieved normal blood glucose levels at this time point, while those in the placebo group saw no meaningful change in glycemic status. Thursday’s readout makes Roche a potential contender in the lucrative obesity market, which is currently dominated by Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide). Despite efforts from the frontrunners to boost their manufacturing capacities, they are both still unable to keep up with the market’s voracious appetite for weight-loss treatments, causing protracted drug shortages. #biotech #biopharma #obesity #weightloss

🔎 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 𝐝𝐫𝐮𝐠 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞𝐬 𝐭𝐨 𝐰𝐚𝐭𝐜𝐡 The rise of GLP-1 agonists has propelled Eli Lilly and Novo Nordisk to the top of the market, with both companies achieving the highest market capitalizations in recent years. With obesity projected to affect a quarter of the global population by 2035, the market for obesity drugs is expected to reach $131 billion within the next five years. New drug candidates are emerging. Here are the ones to watch: 1. CagriSema (Phase III) by Novo Nordisk - A combination of Wegovy and cagrilintide 2. MariTide (Phase II) by Amgen - An injectable bispecific molecule 3. Monlunabant (Phase II) by Novo Nordisk - An oral CB1 receptor blocker acquired from Inversago Pharma 4. APHD-012 (Phase II) by Aphaia Pharma - An oral glucose formulation 5. TERN-601 (Phase I) by Terns Pharmaceuticals - An oral GLP-1 receptor agonist 𝘞𝘩𝘪𝘤𝘩 𝘰𝘧 𝘵𝘩𝘦𝘴𝘦 𝘤𝘢𝘯𝘥𝘪𝘥𝘢𝘵𝘦𝘴 𝘥𝘰 𝘺𝘰𝘶 𝘵𝘩𝘪𝘯𝘬 𝘸𝘪𝘭𝘭 𝘮𝘢𝘬𝘦 𝘪𝘵 𝘵𝘰 𝘵𝘩𝘦 𝘮𝘢𝘳𝘬𝘦𝘵 𝘧𝘪𝘳𝘴𝘵? #drug #obesity #wegovy #ozempic #drjojo Source: https://lnkd.in/dgKEq7uZ ---------- Hi! I am Joanna, and my friends call me Dr Jojo 🌸 𝐈 𝐭𝐚𝐥𝐤 𝐚𝐛𝐨𝐮𝐭 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 𝐚𝐧𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 ♻️ Share this if you find it interesting 🔔 Follow for insights you won't want to miss

-WHO should read this? Commercial, R&D, and BD leaders in pharma and biotech. -WHAT is it about? Novo Nordisk’s Wegovy/Ozempic and Lilly’s Mounjaro were third-quarter standouts, but the exploding obesity category was a theme across many of the big pharma company earnings calls. -WHY is it important? Analysts have enormous long-term projections for anti-obesity medications, particularly after Novo Nordisk reported positive cardiovascular outcomes data for GLP-1 Wegovy, suggesting the drugs have broad benefits beyond weight loss, which will make it harder for payers to deny coverage. It is no surprise that other players are trying to edge their way into the market. In fact, the situation is becoming reminiscent of the early PD-1/L1 days, when nearly every top pharma company with a presence in cancer was scrambling to bring their product into late-stage development. Citeline Norstella #biotech #pharma

So the price share of Viking Therapeutics, Inc. NOW is $28.00 .. it was only $9.00 when I posted the below ten months ago.. enjoy reading "This #product is #unique because of the mechanism of action.. Selective agonist of the thyroid Beta receptors. Thyroid hormone binds to thyroid receptors: *alpha in heart and bones. *Beta mainly in liver and kidneys. So in #theory selective activation of beta receptors would positively affect lipids building up in liver and plasma... without the serious side effects on heart and bones. That was the #vision of Viking Therapeutics, Inc. phase 2 results show significant reduction in lipids on liver plus 20% reduction in blood cholesterol levels.. very #potential product. Selective thyroid beta agonist is a new area but with solid prior information about hyperthyroidism effects on body.. Activation of beta only for periods less than a year would not affect lipids parameters only but affect total body weight.. in a manner (I think) is more effective with less side effects than GLP-1 antagonists. (Wegovy®️). For regional #pharmaceuticals in #jordan and #mena ... find a #startup working on this directions and try to have a #partnership.. PS. still limited number of new #projects in this area. Majdi Sawaked , advancing to phase3 with minimal side effects and good activity in a virgin therapeutic #category .. 50% the stock could ❌ by 10 in 3 years area"

Flagship Pioneering and Pfizer have joined forces to accelerate the development of innovative medicines using #ProFound Therapeutic's proprietary #ProFoundry™ Platform. This collaboration, the first under Flagship's Pioneering Medicines strategic partnership with Pfizer, focuses on discovering novel therapeutics for obesity. Flagship will lead early research, while Pfizer will advance the programs. With projections showing over 50% of adults globally living with overweight/obesity by 2035, Pfizer aims to tap into this lucrative market. Despite challenges with previous #GLP-1RA candidates like #lotiglipron and #danuglipron, Pfizer's shift to a once-daily dosing regimen for #danuglipron shows its commitment to overcoming obstacles. Crucial data expected later this year will shape the molecule's future. #HealthcareInnovation #Pharmaceuticals #MedicalResearch #Obesity #GLP1 #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #MarketEntryStrategy #CompetitiveIntelligence #PartnerIdentification #StrategySupport #ConferenceCoverage Follow our page for more industry updates: https://lnkd.in/dGRWp6FD

Pfizer announced a major milestone in the development of its obesity drug, danuglipron! Danuglipron, an oral GLP-1 receptor agonist, will undergo dose optimization studies in late 2024. This will help determine the best doses for future registration-enabling studies. Dr. Mikael Dolsten, Pfizer's chief scientific officer, highlighted the importance of this development: Obesity is a key therapeutic area for Pfizer, and we believe a once-daily formulation of danuglipron has the potential to be competitive in the oral GLP-1 space. Early results are promising, showing no liver enzyme elevations among over 1,400 participants and supporting once-daily dosing. While danuglipron is still investigational and not yet approved, Pfizer's progress is promising for the future of obesity treatment. Current FDA-approved weight loss medications like Wegovy and Zepbound are weekly injections. Pfizer aims to bring a convenient oral option to the market, pending further trials and FDA approval. #ObesityMatters #Pfizer #Danuglipron #GLP1 #WeightLoss #MedicalResearch #HealthInnovation https://ow.ly/SHhc50SA4Ib

#Flagship Pioneering and #Pfizer have partnered to accelerate the development of innovative medicines using #ProFound Therapeutic's proprietary #ProFoundry™ Platform. This collaboration, the first under Flagship's Pioneering Medicines strategic partnership with Pfizer, focuses on discovering novel therapeutics for obesity. Pioneering Medicines will lead the early research and discovery, and Pfizer will advance the research programs. The World Obesity Federation projects more than 50% of adults globally will be living with overweight/obesity in 2035. Pfizer, like many other companies, seeks to enter this lucrative obesity drug market, following the footsteps of Novo Nordisk and Eli Lilly. However, this is not Pfizer's first attempt. Earlier, its #GLP-1RA drug candidate, #lotiglipron, showed potential signs of liver toxicity during testing, resulting in the discontinuation of its development. Another GLP-1RA candidate, #danuglipron, caused significant gastrointestinal side effects, prompting Pfizer to shift from a twice-daily to a once-daily dosing regimen. Data on the once-daily dosage, anticipated later this year, will be crucial for the molecule's future. Detailed news here: https://lnkd.in/gJXhp5TC Stay updated on the latest trends and news in the pharmaceutical industry. Follow #RASLSS: https://lnkd.in/de5zNWmK #Biotech #Innovation #Pharmaceuticals #ObesityTreatment #DrugDiscovery #Healthcare #LifeSciences #Collaboration #MedicalResearch #FlagshipPioneering #ProFoundTherapeutics #Pfizer #ProFoundryPlatform #TransformationalMedicine #FutureOfMedicine #ProteinTherapeutics #Overweight #Obesity #NovoNordisk #EliLilly

Lilly and Novo Spend Billions to Expand Obesity Pipelines Beyond GLP-1s Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in licensing and M&A deals. Novo Nordisk and Eli Lilly are undoubtedly at the top of the weight loss market. With $1.7 billion in second-quarter sales recorded for Novo’s Wegovy and $1.2 billion for Lilly’s Zepbound, the companies are raking in profits. The two behemoths are likely to remain in that spot until competitors begin to arrive on the market around 2026, according to a report from Pitchbook and Morning Star issued on September 9. But the next wave of drugs, coming from companies like Terns Pharmaceuticals, Structure Therapeutics, Pfizer and Amgen, look like they could beat the current offerings. All these companies could come together to battle for a market Pitchbook estimates could reach $200 billion annually by 2031. But Lilly and Novo are not standing idly by. They’ve been scooping up companies and making deals, diversifying their bets on obesity treatments. And both pharmas are highly anticipated to make further acquisitions in the space, according to the report. Both have also taken smaller bites with licensing deals to explore new targets or next-generation GLP-1 approaches. Obesity is a key investment focus for Novo, executives said during an investor day presentation in March. Of the two, Novo has been the most prolific on the business development stage by far, with 37 partnerships focused on cardiometabolic diseases and obesity, according to the presentations. The company is specifically focused on finding new mechanisms of action. https://lnkd.in/gPraMxbY

🚀 The Obesity Drug Landscape is Evolving: New Players Emerge Beyond GLP-1RAs 🌟 Exciting times for the obesity treatment field! The market is booming, projected to reach $37.1 billion by 2031. While GLP-1 receptor agonists (GLP-1RAs) have been dominant, a wave of innovation is bringing new mechanisms of action (MOAs) to the forefront. **🔍 Beyond the GLP-1RA Mainstay We've seen the success stories of drugs like Wegovy (semaglutide), but there's more to the story. Several companies are exploring novel approaches that target different biological pathways to achieve weight loss. This year (2024) promises exciting developments with upcoming regulatory milestones for drugs like: **APHD-012 (Aphaia Pharma): Mimicking metabolic benefits of bypass surgery without the downsides. (Phase II results expected Q1) **S-309309 (Shionogi): A first-in-class MGAT2 inhibitor for regulating lipid metabolism. (Phase II results expected H1) **bimagrumab (ex-Versanis Biopharmaceuticals, acquired by Eli Lilly): An ACTR2 antagonist potentially offering sustained weight loss with fewer injections. (Phase II results expected H1) 💫 Dual Agonists Take Center Stage Another exciting trend is the rise of dual agonists. These drugs combine mechanisms, often targeting GLP-1 receptors alongside other pathways like GIP receptors. This can potentially lead to increased efficacy and address a broader range of patient needs. Keep an eye on: **cagrisema (Novo Nordisk): Combining a CALCR agonist with semaglutide (GLP-1RA) for potentially superior weight loss. (Phase III results expected H2) **Multiple players (Zealand Pharma, Viking Therapeutics, Amgen, Carmot Therapeutics): Developing various dual GIPR/GLP-1R agonists, offering diverse administration options (injections, frequency). (Phase I/II - Phase III results expected throughout 2024) 🔮 The Future of Obesity Treatment These advancements hold immense promise for a more personalized and effective approach to obesity management. Future research might even focus on increasing brown fat (thermogenic fat) for enhanced calorie burning. #obesity #weightloss #drugdevelopment #pharmaceutical #healthcare #clinicaltrials #GLP-1RA #diabetes #endocrinology